| 1349 |
National Cancer Institute |
Html |
en |
Colon Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of colon cancer. |
| metastatic colorectal carcinoma | 0.379719 |
| Surg Oncol Clin | 0.28139 |
| Engl J Med | 0.307023 |
| trial | 0.267885 |
| Ann Surg | 0.318122 |
| colorectal cancer risk | 0.348524 |
| asymptomatic colorectal cancer | 0.315392 |
| metastatic colorectal cancer | 0.735027 |
| randomized phase | 0.263484 |
| colorectal metastasis | 0.289879 |
| colorectal cancer | 0.918186 |
| solitary colorectal liver | 0.301665 |
| progressive colorectal cancer | 0.31143 |
| Natl Cancer Inst | 0.281801 |
| colorectal metastases | 0.313181 |
| nonpolyposis colorectal carcinoma | 0.307382 |
| Clin Cancer Res | 0.283288 |
| refractory metastatic colorectal | 0.315102 |
| et al. | 0.431822 |
| familial colorectal cancer | 0.339414 |
| colorectal secondaries | 0.290645 |
| colorectal cancer patients | 0.339629 |
| colorectal liver metastases | 0.36614 |
| colorectal cancer survivors | 0.325228 |
|
| colorectal cancer-specific mortality | 0.322283 |
| untreated metastatic colorectal | 0.318138 |
| wild-type metastatic colorectal | 0.314285 |
| Colorectal carcinoma survival | 0.308216 |
| colorectal hepatic metastases | 0.334861 |
| advanced colorectal cancer | 0.418679 |
| Colorectal lung metastases | 0.315994 |
| irinotecan-refractory metastatic colorectal | 0.314278 |
| advanced colorectal carcinoma | 0.299668 |
| colon cancer patients | 0.266011 |
| recurrent colorectal cancer | 0.311799 |
| colorectal adenocarcinoma | 0.293617 |
| colorectal cancer incidence | 0.338171 |
| colorectal cancer disparities | 0.338169 |
| occult colorectal cancer | 0.324742 |
| colorectal cancer rates | 0.338223 |
| hepatic resection | 0.263128 |
| Colorectal Study Group | 0.29718 |
| Abstract | 0.463347 |
| colon cancer | 0.282697 |
| Clin Oncol | 0.692377 |
| colorectal carcinoma | 0.438634 |
| resection | 0.263133 |
| colorectal carcinoma metastases | 0.326025 |
|
CLICK HERE |
| 1416 |
National Cancer Institute |
Html |
en |
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of ovarian epithelial, fallopian tube, and primary peritoneal cancer. |
| relapsed ovarian cancer | 0.50784 |
| recurrent epithelial ovarian | 0.499159 |
| ovarian cancer symptom | 0.524517 |
| gynecologic cancer intergroup | 0.468129 |
| epithelial ovarian carcinoma | 0.585917 |
| chemotherapy | 0.476196 |
| Engl J Med | 0.538958 |
| advanced ovarian cancer | 0.684932 |
| advanced epithelial ovarian | 0.546935 |
| ovarian cancer FIGO | 0.514859 |
| ovarian cancer. | 0.501481 |
| [PUBMED Abstract] | 0.522867 |
| primary peritoneal cancer | 0.467281 |
| ovarian cancer patients | 0.574798 |
| ovarian cancer trials | 0.513542 |
| Ovarian Cancer Registry | 0.525648 |
| ovarian cancer | 0.976385 |
| oncology group study | 0.500359 |
| advanced ovarian epithelial | 0.508108 |
| ovarian carcinoma | 0.617715 |
| Hereditary ovarian cancer | 0.541701 |
| Natl Cancer Inst | 0.533435 |
| Clin Cancer Res | 0.471625 |
| Gynecol Oncol | 0.499118 |
| ovarian carcinoma patients | 0.50527 |
|
| et al. | 0.626141 |
| gynecologic oncology group | 0.583453 |
| Lancet Oncol | 0.480848 |
| refractory ovarian cancer | 0.508349 |
| ovarian cancer—is | 0.495704 |
| ovarian cancers | 0.496625 |
| II-IV ovarian cancer | 0.51385 |
| advanced ovarian carcinoma | 0.5343 |
| ovarian epithelial cancer | 0.539908 |
| residual ovarian cancer | 0.518325 |
| epithelial ovarian cancer | 0.803483 |
| ovarian cancer susceptibility | 0.533409 |
| Brady MF | 0.481715 |
| sporadic ovarian cancer | 0.521614 |
| Abstract | 0.644778 |
| Clin Oncol | 0.718243 |
| platinum-sensitive ovarian cancer | 0.536106 |
| BRCA2-associated ovarian cancer | 0.521842 |
| recurrent ovarian cancer | 0.527704 |
| serous ovarian cancer | 0.529665 |
| Ovarian Neoplasm Group | 0.493177 |
| advanced-stage ovarian cancer | 0.537713 |
| ovarian cancer screening | 0.523447 |
| ovarian cancer syndrome | 0.536708 |
|
CLICK HERE |
| 1500 |
National Cancer Institute |
Html |
en |
Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of non-small cell lung cancer. |
| Lung Cancer Cooperative | 0.310221 |
| lung carcinoma | 0.380451 |
| inoperable lung cancer | 0.309782 |
| early non-small-cell lung | 0.307115 |
| advanced non-small-cell lung | 0.469604 |
| Lung Cancer Study | 0.326026 |
| lung cancer | 0.971767 |
| Lung cancer deaths | 0.317514 |
| nonsquamous non-small-cell lung | 0.297343 |
| phase iii trial | 0.299266 |
| occult lung cancer | 0.305312 |
| early-stage lung cancer | 0.338843 |
| Radiat Oncol Biol | 0.304077 |
| lung cancer survival | 0.297734 |
| Lung Cancer Group | 0.321151 |
| initial lung cancer | 0.317764 |
| Natl Cancer Inst | 0.376584 |
| non-small cell lung | 0.774213 |
| resectable lung cancer | 0.304943 |
| Cochrane Database Syst | 0.296204 |
| inoperable non-small-cell lung | 0.308792 |
| non-small cell carcinoma | 0.303827 |
| extensive-stage non-small-cell lung | 0.295848 |
| non-small-cell lung carcinoma | 0.344111 |
| IIIB/IV non-small-cell lung | 0.298147 |
|
| et al. | 0.437141 |
| Lancet Oncol | 0.323758 |
| metastatic non-small-cell lung | 0.298496 |
| advanced non-small cell | 0.33334 |
| stage lung cancer | 0.3104 |
| nonsmall cell lung | 0.30317 |
| stage non-small-cell lung | 0.297284 |
| PUBMED Abstract | 0.329665 |
| Ann Thorac Surg | 0.373477 |
| Lung Cancer Vinorelbine | 0.296492 |
| Thorac Cardiovasc Surg | 0.329974 |
| lung cancer patients | 0.336644 |
| Cancer Lung Cancer | 0.319239 |
| Abstract | 0.497046 |
| Clin Oncol | 0.544028 |
| cell lung carcinoma | 0.373251 |
| Oncol Biol Phys | 0.305449 |
| lung cancer risk | 0.31701 |
| non-squamous non-small-cell lung | 0.296764 |
| cell lung cancer | 0.689155 |
| IIIB non-small-cell lung | 0.303595 |
| Clin Lung Cancer | 0.316476 |
| resected non-small-cell lung | 0.312654 |
| oncology group | 0.300833 |
|
CLICK HERE |
| 1532 |
National Cancer Institute |
Html |
en |
714-X (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of 714-X as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| peer-reviewed scientific journals | 0.887587 |
| follow-up treatment | 0.710806 |
| cancer cell growth | 0.791188 |
| clinical drug research | 0.768994 |
| transplanted lymphoma cells | 0.825998 |
| camphor-containing compound | 0.745221 |
| -dependent breast cancer | 0.78236 |
| Cancer Terms | 0.744215 |
| ammonia chloride moiety | 0.76714 |
| well-designed clinical trials | 0.748928 |
| IND application process | 0.779791 |
| normal cellular metabolism | 0.86297 |
| cancer information summary | 0.831041 |
| markets 714-X worldwide | 0.83392 |
| breast adenocarcinoma cells | 0.816142 |
| conventional light microscope | 0.751864 |
| high-magnification dark-field microscope | 0.762305 |
| single daily injection | 0.759423 |
| local radiation therapy | 0.743305 |
| Investigational New Drug | 0.768167 |
| estrone sulfatase activity | 0.749881 |
| radiation therapy | 0.757461 |
| usual treatment cycle | 0.783702 |
| immune system cells | 0.780568 |
| dead cells | 0.766188 |
|
| lymphoma tumor models | 0.74615 |
| treatment cycles | 0.709107 |
| peer-reviewed scientific journal | 0.752325 |
| breast cancer cells | 0.935858 |
| 714-X states | 0.744286 |
| tumor cells | 0.75621 |
| camphor component | 0.757515 |
| secrete growth hormones | 0.755571 |
| cancer cells | 0.999087 |
| malignant cells | 0.759464 |
| lymphosarcoma tumor model | 0.750284 |
| 714-X treatment. | 0.746291 |
| human breast cancer | 0.781637 |
| privately funded laboratory | 0.780536 |
| normal cells | 0.757341 |
| 714-X state | 0.740311 |
| animal studies | 0.738772 |
| cancer development | 0.726298 |
| 714-X reportedly works | 0.811434 |
| 3-day rest period | 0.75559 |
| natural killer cells | 0.815748 |
| quality control procedures | 0.767937 |
| camphor vapors | 0.863518 |
| Numerous trace elements | 0.765609 |
|
CLICK HERE |
| 1667 |
National Cancer Institute |
Html |
en |
Pituitary Tumors Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of pituitary tumors. |
| cancer treatment | 0.407234 |
| dexamethasone suppression test | 0.394248 |
| pituitary tumors | 0.908358 |
| body | 0.454559 |
| PDQ cancer information | 0.487589 |
| clinical trials | 0.725513 |
| cancer information summary | 0.446379 |
| clinical trial | 0.553145 |
| Invasive pituitary adenomas | 0.455827 |
| pituitary tumor | 0.646868 |
| treatment clinical trial | 0.392398 |
| PDQ Adult Treatment | 0.388468 |
| transsphenoidal surgery | 0.460842 |
| symptoms | 0.386795 |
| NCI PDQ cancer | 0.400275 |
| radiation therapy | 0.593266 |
| Treatment Editorial Board | 0.409955 |
| general cancer information | 0.38362 |
| treatment | 0.554395 |
| Pituitary Tumors Treatment | 0.478882 |
| magnetic resonance imaging | 0.396976 |
| hormones | 0.440574 |
| non-functioning pituitary tumor | 0.50102 |
| pituitary adenomas | 0.476474 |
|
| cancer cells | 0.443241 |
| pituitary gland | 0.710758 |
| Cancer Information Service | 0.384842 |
| pituitary carcinomas | 0.478569 |
| hormone | 0.451928 |
| treatment clinical trials | 0.429229 |
| National Cancer Institute | 0.477993 |
| spinal cord | 0.43789 |
| growth hormone | 0.42514 |
| lower sex drive | 0.403907 |
| new treatment | 0.437528 |
| drug therapy | 0.42565 |
| stereotactic radiation surgery | 0.403899 |
| Non-functioning pituitary tumors | 0.494237 |
| Benign pituitary adenomas | 0.455748 |
| nuclear magnetic resonance | 0.398799 |
| thyroid-stimulating hormone | 0.404707 |
| extra hormones | 0.398825 |
| cancer clinical trials | 0.398461 |
| recurrent pituitary tumor | 0.483709 |
| cancer information summaries | 0.383614 |
| functioning pituitary tumor | 0.497093 |
| comprehensive cancer information | 0.383142 |
| cancer | 0.645719 |
|
CLICK HERE |
| 1793 |
National Cancer Institute |
Html |
es |
La nutrición en el tratamiento del cáncer (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de las causas y manejo de los problemas de nutrición que se presentan en pacientes de cáncer. |
| alimentos quizás | 0.370325 |
| PDQ Complicaciones | 0.313282 |
| siguientes procedimientos | 0.340481 |
| células madre | 0.550599 |
| nutrientes clave | 0.335265 |
| siguientes elementos | 0.365852 |
| siguientes aspectos | 0.358365 |
| nutriciónLa terapia | 0.324031 |
| siguientes especialistas | 0.336855 |
| abundantes calorÃas | 0.314309 |
| azúcar morena | 0.306423 |
| apoyo nutricional parenteral | 0.676801 |
| alimentos nombre | 0.30449 |
| plantas crucÃferas | 0.309965 |
| nutriciónLos pacientes | 0.345324 |
| siguientes preguntas | 0.30436 |
| folleto consejos | 0.305431 |
| saliva espesa | 0.32646 |
| dentaduras postizas | 0.314487 |
| suficiente aire | 0.303863 |
| La nutrición | 0.791013 |
| paciente coma | 0.327504 |
| parenteralLa nutrición parenteral | 0.367865 |
|
| nutriciónLa radioterapia | 0.32699 |
| Nutrición enteralLa | 0.344949 |
| Fideos macarrones | 0.304814 |
| paciente debilidad | 0.352763 |
| nutriciónLa quimioterapia | 0.324928 |
| siguientes problemas | 0.328941 |
| abundantes proteÃnas | 0.312201 |
| abundante cantidad | 0.303969 |
| pequeñas cantidades | 0.366387 |
| suficientes calorÃas | 0.337397 |
| sección boca | 0.313815 |
| queso crema | 0.306383 |
| suficientes proteÃnas | 0.348155 |
| suficientes alimentos | 0.437599 |
| suficientes nutrientes | 0.304871 |
| estado nutricional ayuda | 0.362928 |
| huevos rellenos | 0.30608 |
| siguientes logros | 0.337047 |
| nutrición parenteral | 0.929054 |
| horarios fijos | 0.305496 |
| siguientes propósitos | 0.338729 |
| cuidado paliativo | 0.310231 |
|
CLICK HERE |
| 1813 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de recto (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de recto. |
| Lippincott Williams | 0.308061 |
| Compton CC | 0.323954 |
| Adults With Colorectal | 0.312555 |
| American Cancer Society | 0.329394 |
| Cancer mortality | 0.316629 |
| Stewart AK | 0.306622 |
| CA Cancer | 0.343818 |
| local recurrence | 0.307246 |
| Cancer Res | 0.329381 |
| DeVita VT Jr | 0.315048 |
| colorectal cancer | 0.983517 |
| intergroup trial int-0089 | 0.308552 |
| ecografÃa endorrectal | 0.343803 |
| recto combinados | 0.312354 |
| Estados Unidos | 0.30658 |
| Natl Cancer Inst | 0.352599 |
| ColoRectal Cancer Group | 0.324874 |
| after curative resection | 0.309771 |
| estadificación tnm | 0.312196 |
| survival is | 0.306383 |
| Colorectal Dis | 0.319303 |
| patients with | 0.357576 |
| Rosenberg SA | 0.307503 |
| Tepper JE | 0.30821 |
| Lawrence TS | 0.307635 |
|
| pT3-pT4 colorectal | 0.31012 |
| circumferential resection margin | 0.307642 |
| Dis Colon Rectum | 0.337841 |
| Cancer Facts | 0.317459 |
| Curr Probl Cancer | 0.317023 |
| after curative | 0.310413 |
| quimiorradioterapia preoperatoria | 0.311684 |
| Cancer Staging Manual | 0.327552 |
| Hereditary Cancer Syndromes | 0.316342 |
| Surg Oncol | 0.34804 |
| PDQ Tratamiento | 0.318445 |
| Cancer invasion | 0.315672 |
| 9th ed | 0.3084 |
| Gastrointestinal Tumor Study | 0.307946 |
| Clin Oncol | 0.415435 |
| Greene FL | 0.306448 |
| recto mide | 0.312331 |
| colorectal carcinoma | 0.311099 |
| systematic review | 0.307729 |
| sección cáncer | 0.306733 |
| large scale adjuvant | 0.307848 |
| recto medio | 0.309555 |
| with colorectal cancer | 0.394477 |
| cancer incidence | 0.328606 |
|
CLICK HERE |
| 1815 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de cuello uterino (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de cuello uterino. |
| Obstet Gynecol | 0.42996 |
| stage iib-iva carcinoma | 0.404466 |
| Massad LS | 0.404333 |
| cervical carcinoma | 0.464118 |
| Bundy BN | 0.406109 |
| adenosquamous carcinomas | 0.405376 |
| Radiat Oncol Biol | 0.406797 |
| stage ib | 0.417647 |
| oncology group study | 0.410713 |
| Natl Cancer Inst | 0.438413 |
| cervical cancer | 0.632715 |
| advanced cervical carcinoma | 0.414377 |
| stage ib squamous | 0.405131 |
| Gynecologic Oncology Group | 0.426077 |
| Cervical stump carcinoma | 0.407575 |
| Gynecol Oncol | 0.448646 |
| patients with | 0.420179 |
| human papillomavirus | 0.464727 |
| early invasive carcinoma | 0.40349 |
| IB cervical carcinoma | 0.422999 |
| Lancet Oncol | 0.403538 |
| Castle PE | 0.404079 |
| adenosquamous cell carcinoma | 0.403688 |
| cervical cytology | 0.405121 |
| cervical smears as | 0.405304 |
|
| estadio ia | 0.405069 |
| squamous cell | 0.407969 |
| cervical carcinoma from | 0.408556 |
| Féderation Internationale | 0.404624 |
| Human papillomavirus type | 0.404678 |
| Cancer Institute Workshop | 0.403618 |
| cervix treated with | 0.403584 |
| estadio ia2 | 0.404118 |
| medically inoperable carcinoma | 0.403293 |
| patients with stage | 0.411753 |
| Clin Oncol | 0.421471 |
| invasive cervical carcinoma | 0.408099 |
| cervical cancers studied | 0.405438 |
| Cervical Cancer Meta-Analysis | 0.408283 |
| Oncol Biol Phys | 0.406905 |
| with cervical carcinoma | 0.410366 |
| cervix with negative | 0.403324 |
| cervical intraepithelial neoplasia | 0.500035 |
| cuello uterino | 0.989011 |
| squamous intraepithelial lesions | 0.406344 |
| treated with | 0.404461 |
| locally advanced | 0.404236 |
| Wright TC Jr | 0.413972 |
| AJCC Cancer Staging | 0.403712 |
|
CLICK HERE |
| 1866 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de labio y de cavidad oral (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de labio y de cavidad oral. |
| adjuvant chemotherapy | 0.438971 |
| Sin embargo | 0.43685 |
| tumor volume measurements | 0.41592 |
| Neck Neoplasms | 0.440866 |
| Merlano M | 0.418057 |
| advanced squamous | 0.428154 |
| inoperable squamous | 0.435102 |
| Arch Otolaryngol Head | 0.440314 |
| Radiat Oncol Biol | 0.538084 |
| Multidisciplinary Approach | 0.478999 |
| Natl Cancer Inst | 0.426444 |
| with cisplatin-containing combination | 0.417426 |
| neck squamous carcinoma | 0.461751 |
| radiation therapy | 0.439011 |
| Head Neck Surg | 0.5075 |
| superficial oral carcinoma | 0.418551 |
| final report | 0.416402 |
| Hong WK | 0.508707 |
| Ensley J | 0.418135 |
| with radiotherapy | 0.424203 |
| Head Neck | 0.61126 |
| neck squamous-cell carcinoma | 0.450172 |
| Kish J | 0.417112 |
| Neck Contracts Program | 0.437615 |
| radioterapia posoperatoria | 0.454665 |
|
| Oral Oncol | 0.423046 |
| Otolaryngol Head Neck | 0.504953 |
| >2 cm | 0.426493 |
| postoperative radiotherapy | 0.416731 |
| oral cavity squamous | 0.417165 |
| lesiones t2 | 0.432316 |
| múltiples ganglios | 0.422477 |
| initially with cisplatin-containing | 0.416896 |
| New York | 0.427836 |
| Clin Oncol | 0.536205 |
| Oncol Biol Phys | 0.544158 |
| Sessions RB | 0.479303 |
| locally advanced squamous | 0.426072 |
| cisplatin-containing combination chemotherapy | 0.424671 |
| Neck Surgery | 0.456161 |
| Combined chemotherapy | 0.419622 |
| neck cancer | 0.956394 |
| treated initially with | 0.417222 |
| unresectable squamous | 0.416233 |
| oral cavity | 0.51028 |
| versus concomitant treatment | 0.418958 |
| locally advanced | 0.441621 |
| neck cancers treated | 0.438026 |
| induction chemotherapy | 0.428539 |
|
CLICK HERE |
| 3602 |
National Cancer Institute |
Html |
en |
Improved Strategies for Cancer Prevention and Early Detection |
The prevention of cancer and the development of more effective strategies to detect cancer precursors and early stage cancers, when treatment may be most effective, remain critical goals. |
| cancer treatment | 0.540152 |
| anal cancer incidence | 0.625627 |
| noncervical cancers | 0.552703 |
| preventive HCV vaccine | 0.546412 |
| research | 0.535928 |
| HPV-positive oropharyngeal cancers | 0.555563 |
| cancer biomarker discovery | 0.573956 |
| cancer develops | 0.60048 |
| cancer biomarker development | 0.580329 |
| early pancreatic disease | 0.537001 |
| smear-based cervical cancer | 0.616538 |
| chronic HCV infection | 0.559892 |
| colorectal cancer | 0.576235 |
| patients | 0.541815 |
| cervical cancer screening | 0.699176 |
| cervical cancers | 0.57226 |
| cervical cancer | 0.761077 |
| HPV vaccine program | 0.571212 |
| chronic HBV infection | 0.541902 |
| cancers | 0.616554 |
| HPV-positive oropharyngeal cancer | 0.594068 |
| oncogenic HPV types | 0.574039 |
| infectious EBV particles | 0.546363 |
| invasive anal cancer | 0.592328 |
| United States | 0.811567 |
|
| HCV infection | 0.652225 |
| pancreatic cancer precursor | 0.587151 |
| percent | 0.591951 |
| transfusion-related HCV infection | 0.564422 |
| pancreatic cancer | 0.645751 |
| precursor lesions | 0.541991 |
| common cancer | 0.538917 |
| pancreatic cancer cells | 0.595973 |
| virus-like particles | 0.540706 |
| early cancer detection | 0.576023 |
| disease | 0.540607 |
| healthy donors | 0.556987 |
| persistent HPV infection | 0.586925 |
| breast cancer | 0.583768 |
| liver cancer mortality | 0.588652 |
| late-stage cancer | 0.546609 |
| HPV infection | 0.707275 |
| cancer risk | 0.57351 |
| lung cancer incidence | 0.625104 |
| cancer | 0.986132 |
| liver cancer | 0.648599 |
| Earlier cancer detection | 0.569503 |
| EBV infection | 0.614356 |
| cancer incidence | 0.636488 |
|
CLICK HERE |